From the Rosetta@home Twitter Account:
Scientists Advance on One of Technology’s Holy Grails
"Designer proteins could help us build new materials, clean up the environment, and even fight COVID-19."


A good read. Includes an update on this Rosetta@home News Article:

The Neo-2/15 anti-cancer protein described on that Nature paper, and to which Rosetta@home contributed with" forward folding experiments used in this study which helped validate designs", will enter human clinical trials "later this year", per David Baker.

"The test is going to be later this year,” he said, referring to the clinical trials for Neo-2/15. “Then we’ll really see what de-novo-designed proteins do inside people.”

---

I did find this presentation from the company that is developing the drug.
It does state that clinical trials are planned for 2021.

On the 6th slide, there's actually a print of the paper linked on the Rosetta@home news article I posted on the OP.

---

I did find this presentation from the company that is developing the drug.
It does state that clinical trials are planned for 2021.

I am almost as impressed by the fact that they have a tie-in to an actual drug developer as I am to the remarkable science.

Most research projects result in a paper or two that someone hopes will influence the development of a real product someday.
This actually does it.

---

Definitely.
The company itself is founded by members/former members of the IPD.
There are actually several of these companies that were basically born at the IPD.

Truly exciting.

---

Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer

"SEATTLE, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the submission of an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration to begin a Phase 1 clinical program of its lead immunotherapeutic candidate, NL-201. NL-201 is a computationally designed de novo protein that is a mimetic of natural cytokines IL-2 and IL-15."

"The Phase 1 study is expected to enroll up to 120 patients with relapsed or refractory solid tumors. Patients will receive intravenous monotherapy with NL-201 in order to assess safety, pharmacokinetics, pharmacodynamics, and antitumor activity. When the recommended dose and schedule are determined, indication-specific expansion cohorts will be enrolled to estimate safety and antitumor activity. In addition to the IND application, Neoleukin has submitted a Clinical Trial Notification (CTN) application for NL-201 in Australia."

---